Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells

Nature Medicine

Volumn 18, Issue 7, 2012, Pages 1095-1101

  Xian, Lingling ^a,b   Wu, Xiangwei ^a,b   Pang, Lijuan ^a,b   Lou, Michael ^a   Rosen, Clifford J ^c   Qiu, Tao ^a   Crane, Janet ^a   Frassica, Frank ^a   Zhang, Liming ^a   Rodriguez, Juan Pablo ^d   Jia, Xiaofeng ^a   Yakar, Shoshana ^e   Xuan, Shouhong ^f   Efstratiadis, Argiris ^f   Wan, Mei ^a   Cao, Xu ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SHIHEZI UNIVERSITY   (China)

^c Maine Medical Center Research Institute   (United States)

^d UNIVERSITY OF CHILE   (Chile)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MASS; BONE MATRIX; BONE MINERALIZATION; BONE REMODELING; CELL ACTIVATION; CELL DIFFERENTIATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; HOMEOSTASIS; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN FUNCTION;

AGING; ANIMALS; BONE AND BONES; BONE MATRIX; BONE RESORPTION; CELL COUNT; CELL DIFFERENTIATION; ENZYME ACTIVATION; FEMUR; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MESENCHYMAL STROMAL CELLS; MICE; MICE, KNOCKOUT; ORGAN SIZE; OSTEOBLASTS; OSTEOGENESIS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RECEPTOR, IGF TYPE 1; TOR SERINE-THREONINE KINASES; X-RAY MICROTOMOGRAPHY;

ADENOVIRIDAE; MAMMALIA; MUS; RATTUS;

EID: 84863726841     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2793     Document Type: Article

References (40)

1. Rizzoli, R., Bianchi, M.L., Garabedian, M., McKay, H.A. & Moreno, L.A. Maximizing bone mineral mass gain during growth for the prevention of fractures in the adolescents and the elderly. Bone 46, 294-305 (2010).
2. Schettler, A.E. & Gustafson, E.M. Osteoporosis prevention starts in adolescence. J. Am. Acad. Nurse Pract. 16, 274-282 (2004).
3. Teitelbaum, S.L. Bone resorption by osteoclasts. Science 289, 1504-1508 (2000).
4. Zaidi, M. Skeletal remodeling in health and disease. Nat. Med. 13, 791-801 (2007). (Pubitemid 47038187)
5. Agnusdei, D. & Gentilella, R. GH and IGF-I as therapeutic agents for osteoporosis. J. Endocrinol. Invest. 28, 32-36 (2005).
6. Belfiore, A., Frasca, F., Pandini, G., Sciacca, L. & Vigneri, R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr. Rev. 30, 586-623 (2009).
7. Giustina, A., Mazziotti, G. & Canalis, E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr. Rev. 29, 535-559 (2008).
8. Yakar, S. & Rosen, C.J. From mouse to man: redefining the role of insulin-like growth factor-I in the acquisition of bone mass. Exp. Biol. Med. (Maywood) 228, 245-252 (2003). (Pubitemid 36314490)
9. Yakar, S., Pennisi, P., Wu, Y., Zhao, H. & LeRoith, D. Clinical relevance of systemic and local IGF-I. Endocr. Dev. 9, 11-16 (2005).
10. Amin, S. et al. High serum IGFBP-2 is predictive of increased bone turnover in aging men and women. J. Bone Miner. Res. 22, 799-807 (2007). (Pubitemid 351339739)
11. Ohlsson, C. et al. The role of liver-derived insulin-like growth factor-I. Endocr. Rev. 30, 494-535 (2009).
12. Seck, T. et al. Concentration of insulin-like growth factor (IGF)-I and-II in iliac crest bone matrix from pre-and postmenopausal women: relationship to age, menopause, bone turnover, bone volume, and circulating IGFs. J. Clin. Endocrinol. Metab. 83, 2331-2337 (1998). (Pubitemid 28503023)
13. Yamaguchi, T. et al. Serum levels of insulin-like growth factor (IGF); IGF-binding proteins-3,-4, and-5; and their relationships to bone mineral density and the risk of vertebral fractures in postmenopausal women. Calcif. Tissue Int. 78, 18-24 (2006). (Pubitemid 43107288)
14. Hill, P.A. Bone remodelling. Br. J. Orthod. 25, 101-107 (1998).
15. Abe, E. et al. TSH is a negative regulator of skeletal remodeling. Cell 115, 151-162 (2003). (Pubitemid 37329579)
16. Mundy, G.R. & Elefteriou, F. Boning up on ephrin signaling. Cell 126, 441-443 (2006). (Pubitemid 44163612)
17. Tang, Y. et al. TGF-β1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat. Med. 15, 757-765 (2009).
18. Bautista, C.M., Mohan, S. & Baylink, D.J. Insulin-like growth factors I and II are present in the skeletal tissues of ten vertebrates. Metabolism 39, 96-100 (1990). (Pubitemid 20027714)
19. Canalis, E., Pash, J., Gabbitas, B., Rydziel, S. & Varghese, S. Growth factors regulate the synthesis of insulin-like growth factor-I in bone cell cultures. Endocrinology 133, 33-38 (1993). (Pubitemid 23206371)
20. Pfeilschifter, J. et al. Parathyroid hormone increases the concentration of insulin-like growth factor-I and transforming growth factor β 1 in rat bone. J. Clin. Invest. 96, 767-774 (1995).
21. Hayden, J.M., Mohan, S. & Baylink, D.J. The insulin-like growth factor system and the coupling of formation to resorption. Bone 17, 93S-98S (1995).
22. Rodda, S.J. & McMahon, A.P. Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development 133, 3231-3244 (2006). (Pubitemid 44404346)
23. Callewaert, F., Sinnesael, M., Gielen, E., Boonen, S. & Vanderschueren, D. Skeletal sexual dimorphism: relative contribution of sex steroids, GH-IGF1, and mechanical loading. J. Endocrinol. 207, 127-134 (2010).
24. Russell, R.C., Fang, C. & Guan, K.L. An emerging role for TOR signaling in mammalian tissue and stem cell physiology. Development 138, 3343-3356 (2011).
25. Harrison, D.E. et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460, 392-395 (2009).
26. Selman, C. et al. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 326, 140-144 (2009).
27. Liu, L. & Parent, C.A. Review series: TOR kinase complexes and cell migration. J. Cell Biol. 194, 815-824 (2011).
28. Blüher, M., Kahn, B.B. & Kahn, C.R. Extended longevity in mice lacking the insulin receptor in adipose tissue. Science 299, 572-574 (2003). (Pubitemid 36135156)
29. Bonjour, J.P., Chevalley, T., Ferrari, S. & Rizzoli, R. The importance and relevance of peak bone mass in the prevalence of osteoporosis. Salud Publica Mex. 51 (suppl. 1), S5-S17 (2009).
30. Liu, J.M. et al. IGF-1 as an early marker for low bone mass or osteoporosis in premenopausal and postmenopausal women. J. Bone Miner. Metab. 26, 159-164 (2008).
31. Ohlsson, C. et al. Older men with low serum IGF-1 have an increased risk of incident fractures: the MrOS Sweden study. J. Bone Miner. Res. 26, 865-872 (2011).
32. Hauschka, P.V., Mavrakos, A.E., Iafrati, M.D., Doleman, S.E. & Klagsbrun, M. Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. J. Biol. Chem. 261, 12665-12674 (1986). (Pubitemid 17204223)
33. Lamberts, S.W., van den Beld, A.W. & van der Lely, A.J. The endocrinology of aging. Science 278, 419-424 (1997). (Pubitemid 27454418)
34. Tatar, M., Bartke, A. & Antebi, A. The endocrine regulation of aging by insulin-like signals. Science 299, 1346-1351 (2003). (Pubitemid 36254639)
35. Ziv, E. & Hu, D. Genetic variation in insulin/IGF-1 signaling pathways and longevity. Ageing Res. Rev. 10, 201-204 (2011).
36. Mohan, S. & Baylink, D.J. Serum insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5 levels in aging and age-associated diseases. Endocrine 7, 87-91 (1997). (Pubitemid 127483093)
37. Boonen, S. et al. Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study. J. Clin. Endocrinol. Metab. 87, 1593-1599 (2002). (Pubitemid 34615245)
38. Yakar, S. et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc. Natl. Acad. Sci. USA 96, 7324-7329 (1999). (Pubitemid 29299660)
39. Kuznetsov, S. & Gehron, R.P. Species differences in growth requirements for bone marrow stromal fibroblast colony formation in vitro. Calcif. Tissue Int. 59, 265-270 (1996). (Pubitemid 26353021)
40. Di Gregorio, G.B. et al. Attenuation of the self-renewal of transit-amplifying osteoblast progenitors in the murine bone marrow by 17 β-estradiol. J. Clin. Invest. 107, 803-812 (2001). (Pubitemid 32274033)